[{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Afuresertib","moa":"||Pan-AKT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAE120","moa":"USP-1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Laekna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LAE001","moa":"CYP17","graph1":"Oncology","graph2":"Phase II","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laekna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laekna Therapeutics \/ Inapplicable"}]

Find Oncology Clinical Drug Pipeline Developments & Deals by Laekna Therapeutics

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : LAE120 is an novel USP1 inhibitor drug candidate, being investigated for the treatment of advanced solid tumors.

                          Product Name : LAE120

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : LAE120

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 inhibitor) is being developed in patients with mCRPC following standard of care (SOC) treatment.

                          Product Name : LAE001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 23, 2024

                          Lead Product(s) : LAE001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : LAE002 (Afuresertib) a potent next-generation small molecule pan-AKT kinase inhibitor in combination with sintilimab and chemotherapy, targets patients with specific solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors.

                          Product Name : LAE002

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 01, 2022

                          Lead Product(s) : Afuresertib,Sintilimab,Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Innovent Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : Afuresertib is a clinically proven, highly potent small-molecule pan-AKT inhibitor. Afuresertib is being studied in global clinical studies in four different cancers including ovarian cancer, prostate cancer, triple-negative breast cancer, and HR+/HER2- ...

                          Product Name : LAE002

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 26, 2021

                          Lead Product(s) : Afuresertib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) that blocks both androgen and aldosterone synthesis, Therefore, unlike abiraterone acetate, LAE001 does not need a co-medication of prednisone.

                          Product Name : LAE001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 26, 2021

                          Lead Product(s) : LAE001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank